Table 3

Inferential results

Remission
(N=6)
Recurrence
(N=20)
Inferential test coefficientp Value
Demographic and disease characteristic parameters
 Age55±6.3955.30±16.28t (21.75)=−0.070.947
 Male gender2/618/20x2 (1)=8.350.013
 BMI29.60±5.4725.57±2.43t (5.60)=1.750.134
 Duration of PsA (years)3 ±1.417.6±7.33U=34.50; z=−1.570.116
 Duration of remission (months)19.50±16.7425.25±25.62U=51.50; z=−0.5210.602
 Use of anti-TNF-α2/610/20x2 (1)=0.520.652
 Duration of DMARD (months)37.83±12.6733±14.52U=37.00; z=−0.6230.533
 Duration of TNFi (months)37±1.4142±39.70U=6.50; z=−0.7530.451
 TJC0.33±0.820.15±0.49U=55.50; z=−0.490.622
 SJC0.17±0.410.05±0.22U=53.00; z=−0.9220.356
 VAS patient global (cm)0.96±1.200.79±0.88U=43.00; z=−0.3260.744
 VAS patient pain (cm)0.95±0.680.61±0.79U=26.50; z=-0.8500.395
 VAS physician global (cm)0.18±0.400.08±0.17U=48.00; z=−0.1940.846
 CRP (mg/dL)1.82±2.471.74±1.99U=49.50; z=−0.6400.522
 ESR10±5.668.13±8.46U=32.00; z=−1.1850.236
Composite scores
 DAS-28 CRP1.52±0.351.33±0.36U=30.50; z=−1.2120.225
 DAPSA2.14±1.601.79±1.69U=29.00; z=−0.5960.551
 PASDAS1.15±0.6241.11±0.83U=39.00; z=−0.4470.655
 HAQ-DI0.17±0.190.16±0.49U=42.00; z=−1.4030.161
 SF-36 (physical component)50.16±5.7150.74±9.98U=43.00; z=−0.7330.463
 SF-36 (psychological component)51.62±6.7453.32±6.40U=46.00; z=−0.5330.594
 FACIT-F44.25±7.8045.17±6.71U=32.00; z=−0.3420.732
 BASDAI2.12±1.311.39±1.11t (5.69)=1.140.301
 PASI0±00.28±0.63t (19)=1.990.061
 NAPSI1.83±2.485.05±7.65U=43.00; z=−1.0590.289
US findings joints
 Hypertrophy0±00.50±1.15t (19)=1.950.066
 Effusion3±24.10±4.61U=58.00;z=−0.1230.902
 Power Doppler0.17±0.410.10±0.31U=56.00;z=−0.4400.660
US findings entheseal sites
 Enthesophyte0.33±0.820.10±0.45U=53.00; z=−0.9220.356
 Calcifications3±3.295±3.43t (24)=−1.260.220
 Erosions0.33±0.820.55±0.89U=52.50; z=−0.600.555
 Bursitis0.17±0.410.05±0.22U=53.00; z=−0.9220.356
 Vascularisation0±00.10±0.31t (19)=1.450.163
  • Indicated are mean±SD, except for gender and use of TNFi that indicate the total number of patients.

  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAPSA, Disease Activity index for Psoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area Severity Index; NAPSI, Nail Psoriasis Severity Index; SJC, Swollen Joint Count; TJC, Tender Joint Count; VAS, visual analogue scale.